<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group|1</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">9743300</article-id><article-id pub-id-type="pmc">2062972</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>High-dose intensity cyclophosphamide, epidoxorubicin, vincristine and prednisone by shortened intervals and granulocyte colony-stimulating factor in non-Hodgkin's lymphoma: a phase II study.</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Pronzato</surname><given-names>P.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Lionetto</surname><given-names>R.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Botto</surname><given-names>F.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Pensa</surname><given-names>F.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Tognoni</surname><given-names>A.</given-names></name></contrib></contrib-group><aff>Department of Medical Oncology, Ospedale S. Andrea, Loc Felettino, La Spezia, Italy.</aff><pub-date pub-type="ppub"><month>9</month><year>1998</year></pub-date><volume>78</volume><issue>6</issue><fpage>777</fpage><lpage>780</lpage><abstract><p>Twenty patients with non-Hodgkin's lymphoma were treated with a combination of cyclophosphamide (750 mg m(-2), day 1), epidoxorubicin (60 mg m(-2), day 1), vincristine (1.4 mg m(-2), day 1) and prednisone (100 mg m(-2), days 1-5) every 14 days. Shortening of intervals was associated with the prophylactic employment of granulocyte colony-stimulating factor (G-CSF; specifically, filgrastim) administered at a dose of 300 microg subcutaneously from day 6 to day 11. The ratio between actually delivered dose intensity and planned dose intensity was 1.0 in 18 out the 20 patients. Toxicity was acceptable; response rate and survival are in the expected range. The present study demonstrated the feasibility of acceleration of chemotherapy cycles to obtain dose intensification in non-Hodgkin's lymphoma.</p></abstract></article-meta></front><body><supplementary-material content-type="scanned-pages"><graphic xlink:href="brjcancer00006-0083.tif" xlink:title="scanned-page" xlink:role="777" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00006-0084.tif" xlink:title="scanned-page" xlink:role="778" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00006-0085.tif" xlink:title="scanned-page" xlink:role="779" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00006-0086.tif" xlink:title="scanned-page" xlink:role="780" mimetype="image" mime-subtype="tiff"/></supplementary-material></body></article>

